STEVENSON, Md., July 17, 2017 -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of Georgia on behalf of purchasers of HD Supply Holdings, Inc. (Nasdaq:HDS) (“HD” or the “Company”) securities during the period between November 9, 2016 and June 5, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until September 11, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in HD securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that HD’s 2017 operating and growth leverage guidance was not feasible, the recovery of its Facilities Maintenance (“FM”) supply chain was not in line with prior expectations and planning, and the sale of its Waterworks segment was being explored.
According to the complaint, following a June 6, 2017 report of divestiture of one of its main business segments and increase capital investments in its FM segment, the value of HD shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in HD securities purchased on or after November 9, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 [email protected]


CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 



